Business Wire

THE-BRIJ

19.12.2022 12:53:36 CET | Business Wire | Press release

Share
Introducing THE BRIJ - A World of Arts and Culture

Serendipity Arts today announced its vision to bring the arts to life through a cutting-edge arts and culture centre, that will be a bridge that connects the world to the arts, and its transformational power. THE BRIJ will dedicate space, time, and resources to create ground-breaking art that is transformational and meaningful. Through this centre, Serendipity Arts also hopes to spark conversations around the arts across the South Asian region worldwide, assimilating regional flavours, traditions, and cultures, while also building a sustainable artistic ecosystem. The upcoming institution is named after and pays homage to late Mr. Brijmohan Lall Munjal, Indian industrialist and visionary, Mr. Sunil Kant Munjal’s father.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221218005083/en/

Outlining the idea behind THE BRIJ, Mr. Sunil Kant Munjal, Founder & Patron of Serendipity Arts and Founder of THE BRIJ, said, “Our privileges always come with responsibility; this initiative is a responsibility and a passion project for us. THE BRIJ stems from a responsibility we feel towards the arts; the way art is seen today, compared to how it was perceived in the region, prior to colonization. In terms of its programming, THE BRIJ will retain the aura of the flagship festival while adding multiple layers of practice, learning and experimentation to its programs, around the year. Planned around diverse creative practices, the facility will have higher arts education, incubation labs, centres of cultural innovation, performance spaces, and museums at a never-before-seen scale, in an interdisciplinary manner. In effect it will be the complete ecosystem for Arts & Culture at one place.”

The three essential elements of the Centre will be Education & Research, Multidisciplinary Experiences and Innovation & Incubation with training, workshops, and residencies. The one-of-its-kind centre is currently under construction and will have a Museum, an Academy & Workshop, a Gallery, Library, a Stepwell Gallery, an Arena, Theatre and Black Box, and much more. The facility will also house a crafts centre and an artisanal village, where dying and fringe art & craft forms will be brought back to life, through research, practice, and incubation. The entire campus has been designed in a way that it is 100 percent accessible to the differently abled.

With interdisciplinarity, education, and intergenerational exchange as its key purposes, THE BRIJ will emphasise excellence, change, innovation, equality, integrity, and responsibility. The aim is to gift the city of Delhi and the nation a cultural centre, enabling visitors with a shared passion and curiosity for the arts to cherish and immerse in it, inclusively. The centre hopes to create a space that attracts academics, intellectuals, students, art lovers, critics, artists, and members of the public, who can come together to create a bustling creative community.

With cutting-edge technologies that promise to bring forth unique and engaging experiences for visitors, THE BRIJ will be truly global in form and spirit. It will have all the ingredients for an inclusive and immersive experience with assisted navigation and omnichannel availability, while also driving the imperatives of sustainability through a reduced carbon footprint. At the same time, an efficient operational backend, a robust infrastructure for security and connectivity, and futuristic technologies will support the museum and the dream.

Speaking about THE BRIJ, Ms Smriti Rajgarhia, Director, Serendipity Arts Foundation and Festival, said,THE BRIJ is our endeavour to strengthen India’s place in the global cultural dialogue and make international art accessible to the discerning and the common enthusiast. We aim to contribute to the cultural quotient of the region, through restored artworks and revival of lost or at-risk art forms, while also seeking to redefine the future of arts through interdisciplinary collaboration and innovation.”

Among the many features that make this cultural centre unique are the twin driving forces of economy and sustainability, both of which find expression through this building. THE BRIJ will also aim to meet the Foundation’s aspiration to emerge as a catalyst for change, by creating employment opportunities, contributing to India’s and New Delhi’s cultural economy and attracting both Indian and international tourists. Courtesy of Serendipity Arts, THE BRIJ already has and will further enhance its partnerships and exchanges with global institution and creative organizations, to build a facility with state-of-the-art infrastructure, that is organic and future facing.

The entire campus of THE BRIJ would have a platinum rating for green buildings and will generate more than 5200 direct and indirect employment. Besides, more than 120,000 people are expected to benefit from the education and skilling programmes that will be made available. About 90,000 young learners will have free access to the museum, with over 200 art start-ups and projects supported through the incubation centre. Through its multilateral and multicultural platform, the one-of-its-kind Museum hopes to significantly contribute to India’s GDP.

Speaking on the initiative, key member of our expert panel of architects, Mr. Dikshu Kukreja, Managing Principal, CP Kukreja Architects (CPKA), New Delhi, said, “The design philosophy for THE BRIJ is to create a co-existential architecture where the building and landscape dissolve into one. The architecture amplifies its context with buildings envisioned as magnified rock outcrops just like the quartzite rock formations found on the site. The design allows the adjoining forest to permeate into the site. All this as the vibrant and varied programmatic elements form a musical ensemble experiencing hitherto unexplored and futuristic sustainable design strategies.”

In addition to Mr Sunil Kant Munjal, THE BRIJ is also the dream of patron and social entrepreneur Shefali Munjal, Founder-Patron of THE BRIJ. The Board of Advisors include media personality and the current Chair of the Royal College of Arts, UK, Sir Peter Bazelgette; Harsh Goenka, Chairman of the RPG Group, an ardent collector of art and a strong advocate for fostering innovation; and Deepak Iyer, who heads the Accenture Microsoft Business group for Southeast Asia.

Advisors for THE BRIJ include poet, cultural theorist, and curator Ranjit Hoskote; Manu Chandra, Chef Partner for THE BRIJ and one of the pioneers of the gastropub scene in India; Shubha Mudgal, Padma Shri recipient and winner of the Gold Plaque Award for Special Achievement in Music at the Chicago International Film Festival; Aneesh Pradhan, noted table player; and Anuradha Kapur, recipient of the Sangeet Natak Award for Direction in Theatre and the instrumental figure at the National School of Drama, Delhi and Bangalore.

For more details, visit www.thebrij.world

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221218005083/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye